FDA approves Novo Nordisk’s diabetes drugs

(Reuters) – The U.S. Food and Drug Administration said it approved two diabetes drugs from Danish drugmaker Novo Nordisk A/S to be marketed in the country.

The FDA approved the drugs, Tresiba and Ryzodeg, with a warning that they should not be used in patients who have high levels of the chemical ketone. (http://1.usa.gov/1MOio9w)

(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)

• Pharmaceuticals Drug Trials
• Health
• Food and Drug Administration